Cargando…

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

Detalles Bibliográficos
Autores principales:	Ratner, L, Rauch, D, Abel, H, Caruso, B, Noy, A, Barta, S K, Parekh, S, Ramos, J C, Ambinder, R, Phillips, A, Harding, J, Baydoun, H H, Cheng, X, Jacobson, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817103/ https://www.ncbi.nlm.nih.gov/pubmed/27015285 http://dx.doi.org/10.1038/bcj.2016.21

Ejemplares similares

Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
por: Ratner, Lee, et al.
Publicado: (2015)

Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma
por: Ratner, Lee, et al.
Publicado: (2009)

Inducible nitric oxide synthase mediates DNA double strand breaks in Human T-Cell Leukemia Virus Type 1-induced leukemia/lymphoma
por: Baydoun, Hicham H, et al.
Publicado: (2015)

Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma
por: Sparano, Joseph A., et al.
Publicado: (2020)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Akt activation by human T-cell leukemia virus tax oncoprotein
por: Cherian, Mathew, et al.
Publicado: (2015)

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023)

Adult T-Cell Leukemia-Lymphoma Presenting Concurrently with Myelopathy
por: Poondru, Sneha, et al.
Publicado: (2022)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Targeting NF-κB with Nanotherapy in a Mouse Model of Adult T-Cell Leukemia/Lymphoma
por: Rauch, Daniel A., et al.
Publicado: (2021)

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)
por: Ramos, Juan C., et al.
Publicado: (2018)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia
por: Du, Xin, et al.
Publicado: (2017)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?
por: Jessamy, Kegan, et al.
Publicado: (2016)

Epochs in the History of Obstetrics
por: Greer, H. L. H.
Publicado: (1935)

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
por: La Starza, Roberta, et al.
Publicado: (2019)

Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia
por: Wirth, Ingrid M., et al.
Publicado: (2020)

Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma
por: Rauch, Daniel A., et al.
Publicado: (2020)

Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma
por: Barta, Stefan K, et al.
Publicado: (2010)

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation
por: Ozasa, Ryotaro, et al.
Publicado: (2012)

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report
por: Chan, Steven M, et al.
Publicado: (2009)

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
por: Bista, Ranjan, et al.
Publicado: (2017)

Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report
por: Obeidat, Mohammad Bader, et al.
Publicado: (2020)

Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR Leukemia Cells
por: Kyca, Tomáš, et al.
Publicado: (2021)

Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment
por: Ratner, Lee
Publicado: (2019)

Epigenetic Regulation of Human T-Cell Leukemia Virus Gene Expression
por: Ratner, Lee
Publicado: (2021)

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells
por: Ohyashiki, Junko H, et al.
Publicado: (2008)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wilson, Wyndham H., et al.
Publicado: (2021)

The cubist epoch
por: Cooper, Douglas, 1911-1984
Publicado: (1970)

The Psychology of Epochs
Publicado: (1852)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
por: Vassilakopoulos, T., et al.
Publicado: (2022)

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2015)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib
por: Ali, Naveed, et al.
Publicado: (2016)

Bortezomib suppresses self‐renewal and leukemogenesis of leukemia stem cell by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐rearranged myeloid leukemia
por: Zhou, Bin, et al.
Publicado: (2021)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vrmth2uqgc262q3q5af994n99s